It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HOLX’s FA Score shows that 0 FA rating(s) are green whileTMO’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HOLX’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
HOLX (@Medical Specialties) experienced а -5.95% price change this week, while TMO (@Medical Specialties) price change was -1.23% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.08%. For the same industry, the average monthly price growth was +3.94%, and the average quarterly price growth was +5.39%.
HOLX is expected to report earnings on Jan 29, 2025.
TMO is expected to report earnings on Jan 29, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
HOLX | TMO | HOLX / TMO | |
Capitalization | 17.9B | 220B | 8% |
EBITDA | 1.06B | 11.1B | 10% |
Gain YTD | 1.134 | -0.096 | -1,177% |
P/E Ratio | 36.08 | 37.38 | 97% |
Revenue | 3.97B | 42.9B | 9% |
Total Cash | 1.93B | 8.08B | 24% |
Total Debt | 2.58B | 34.9B | 7% |
HOLX | TMO | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 37 | 34 | |
SMR RATING 1..100 | 68 | 62 | |
PRICE GROWTH RATING 1..100 | 61 | 58 | |
P/E GROWTH RATING 1..100 | 92 | 67 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (67) in the Medical Specialties industry is in the same range as HOLX (69). This means that TMO’s stock grew similarly to HOLX’s over the last 12 months.
TMO's Profit vs Risk Rating (34) in the Medical Specialties industry is in the same range as HOLX (37). This means that TMO’s stock grew similarly to HOLX’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as HOLX (68). This means that TMO’s stock grew similarly to HOLX’s over the last 12 months.
TMO's Price Growth Rating (58) in the Medical Specialties industry is in the same range as HOLX (61). This means that TMO’s stock grew similarly to HOLX’s over the last 12 months.
TMO's P/E Growth Rating (67) in the Medical Specialties industry is in the same range as HOLX (92). This means that TMO’s stock grew similarly to HOLX’s over the last 12 months.
HOLX | TMO | |
---|---|---|
RSI ODDS (%) | 2 days ago66% | 2 days ago69% |
Stochastic ODDS (%) | 2 days ago66% | 2 days ago53% |
Momentum ODDS (%) | 2 days ago56% | 2 days ago51% |
MACD ODDS (%) | 2 days ago55% | 2 days ago72% |
TrendWeek ODDS (%) | 2 days ago57% | 2 days ago58% |
TrendMonth ODDS (%) | 2 days ago56% | 2 days ago62% |
Advances ODDS (%) | 9 days ago57% | 3 days ago60% |
Declines ODDS (%) | 2 days ago51% | 7 days ago62% |
BollingerBands ODDS (%) | 2 days ago59% | 2 days ago64% |
Aroon ODDS (%) | 2 days ago49% | 2 days ago47% |
A.I.dvisor indicates that over the last year, HOLX has been loosely correlated with MDT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HOLX jumps, then MDT could also see price increases.
Ticker / NAME | Correlation To HOLX | 1D Price Change % | ||
---|---|---|---|---|
HOLX | 100% | -0.25% | ||
MDT - HOLX | 45% Loosely correlated | +0.02% | ||
XRAY - HOLX | 42% Loosely correlated | -2.04% | ||
TMO - HOLX | 39% Loosely correlated | -0.27% | ||
LH - HOLX | 38% Loosely correlated | +0.58% | ||
SNN - HOLX | 36% Loosely correlated | +0.47% | ||
More |
A.I.dvisor indicates that over the last year, TMO has been closely correlated with DHR. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then DHR could also see price increases.
Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
---|---|---|---|---|
TMO | 100% | -0.27% | ||
DHR - TMO | 75% Closely correlated | -0.28% | ||
A - TMO | 65% Loosely correlated | -0.88% | ||
RVTY - TMO | 61% Loosely correlated | -0.36% | ||
BRKR - TMO | 53% Loosely correlated | +1.10% | ||
ILMN - TMO | 45% Loosely correlated | -0.89% | ||
More |